The 1 AI Stock I'd Put in a Time Capsule and Open in 2036

Absci is presented as a long-duration AI-biotech story, using generative AI to design protein drugs before lab testing and pairing that with a wet-lab platform. The article cites validation from partnerships with Merck, PrecisionLife, and Owkin, while noting meaningful risks from clinical failure, dilution, and the long path to monetization. The core thesis is that if even one homegrown program succeeds, the company could eventually generate royalty streams and owned product economics.

Analysis

ABSI is a classic long-duration optionality name: the market is still valuing it like a development-stage discovery vendor, while the real upside is a platform take-rate on future biologics if its design-engine actually compounds. The second-order effect is that successful validation with large pharma should reduce the perceived probability that AI is merely speeding up early R&D without improving clinical hit-rate; that matters because the equity upside comes less from single-program success than from convincing counterparties to keep feeding the platform with targets.

The competitive dynamic is more subtle than “AI biotech wins.” If Absci keeps landing blue-chip partners, the scarce resource becomes not model quality but access to high-value targets and wet-lab throughput. That would pressure smaller discovery shops and CROs that compete on speed alone, while benefiting enablers with screening, analytics, and lab automation exposure. On the other hand, if capital markets stay tight, dilution can become the main driver of returns, and even good scientific news may not translate into stock performance unless it is paired with non-dilutive partnering cash.

The key catalyst path is binary and slow: partner expansion and preclinical-to-clinical conversion over months, but real re-rating only if one internally generated asset reaches human data over the next 1-3 years. The tail risk is that AI improves cycle time but not translational biology, leaving Absci with a better story and no economic moat. Another underappreciated risk is that success by a handful of big-platform peers could compress Absci's multiple if investors decide the category is becoming crowded and undifferentiated.

Consensus appears to be overpaying for the narrative and underpricing the balance-sheet drag. The better framing is not “AI drug discovery is hot,” but “how much of the current equity value can be justified without assuming one clinical win?” If the answer is close to zero, the stock should trade as a financed call option, not a core compounder. That argues for disciplined entry after financing overhangs or data events, not chase buying on partnership headlines.

Key Decisions for Investors

• Long ABSI as a small, convex starter position only after the next financing window is known; size it as a 6-12 month call on platform validation, not a fundamental compounder.
• Sell near-term upside volatility in ABSI via call overwrites into partnership-driven spikes; the stock is likely to overreact on headlines while the true value inflection is 12-36 months away.
• Pair trade: long NVDA / short ABSI or long NBIS / short ABSI if you want AI exposure with operating leverage and lower binary clinical risk; ABSI should underperform pure-play infrastructure on any risk-off tape.
• Add ABSI only on confirmed non-dilutive partnership economics or first-in-human data from an internally created asset; those are the two events that can re-rate the name by 2-3 turns if credible.
• Avoid chasing on broad AI enthusiasm; if biotech multiples compress, ABSI is likely to de-rate faster than large-cap AI because its valuation depends on distant royalties and uncertain clinical conversion.